Loading stock data…
AORT
$26.50-8.91 (-25.17%)
Market OpenUpdated 2:20 PM EDT
Artivion, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Artivion, Inc. in the Healthcare sector is trading at $25.73. The stock is currently 47% below its 52-week high of $48.25, remaining 36.8% below its 200-day moving average. Technical signals show oversold RSI of 19 and bearish MACD signal, explaining why AORT maintains its current current market pressure. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 19) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$26.50
Potential Downside
90.3%
Whystock Fair Value$2.58
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; C...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.80B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
176.95
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.62
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-4.00%
Volume
Today's trading volume
3.92M
Recent News
Artivion (AORT) Q1 Earnings and Revenues Surpass Estimates
Artivion (AORT) delivered earnings and revenue surprises of +33.33% and +0.33%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Artivion (AORT) Q1 2026 Earnings Transcript
Joining me from Artivion, Inc.'s management team are Pat Mackin, CEO, and Lance Berry, COO and CFO. Comments made on this call that look forward in time involve risks and uncertainties and are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements include statements made as to the company’s or management’s intentions, hopes, beliefs, expectations, or predictions of the future.
Artivion’s (NYSE:AORT) Q1 CY2026 Earnings Results: Revenue In Line With Expectations
Medical device company Artivion (NYSE:AORT) met Wall Street’s revenue expectations in Q1 CY2026, with sales up 17.5% year on year to $116.3 million. On the other hand, the company’s full-year revenue guidance of $488 million at the midpoint came in 1.5% below analysts’ estimates. Its non-GAAP profit of $0.08 per share was 35.1% below analysts’ consensus estimates.
3 Reasons to Avoid AORT and 1 Stock to Buy Instead
Over the last six months, Artivion’s shares have sunk to $37.03, producing a disappointing 18.2% loss - a stark contrast to the S&P 500’s 3.9% gain. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.
Strong Catalysts Drive Artivion (AORT)
Conestoga Capital Advisors, an asset management company, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The first quarter of 2026 began with optimism about the domestic economy and attractive Small Cap valuations, but was impacted by volatility from Middle East geopolitical unrest and changing interest rate expectations. This unrest drove […]